Investor and Media Contact:
Michelle Edwards, Investor Relations
medwards@oxigene.com
415-315-9413
OXiGENE Announces Clinical Trials Interim Data Update to be Presented at the
12th Biennial Meeting of the International Gynecologic Cancer Society
WALTHAM, MA -- October 21, 2008 -- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a
clinical-stage, biopharmaceutical company developing novel therapeutics to treat
cancer and eye diseases, announced today that data from clinical trials with its
vascular disrupting agent (VDA) product candidate, ZYBRESTAT (fosbretabulin)
(formerly referred to as combretastatin A4 phosphate / CA4P), will be presented
at the upcoming 12th Biennial Meeting of the International Gynecologic Cancer
Society in Bangkok, Thailand, October 25-28, 2008.
Paper Presentation:
Abstract #315: FOSBRETABULIN (COMBRETASTATIN A4 PHOSPHATE [CA4P]) CARBOPLATIN
AND PACLITAXEL IS ACTIVE IN PATIENTS WITH PLATINUM RESISTANT OVARIAN CANCER;
Poster presentation by Gordon Rustin, MB.BS, MSC, MD, FRCP, Northwood, United
Kingdom, on Saturday, October 25th, 2008. Poster Session 1: Category C: OVARIAN
CANCER; 08:00-19:00h in the Poster Area, Queen Sirikit National Convention
Center.
About ZYBRESTAT
ZYBRESTAT (fosbretabulin) is currently being evaluated in a pivotal registration
study as a potential treatment for anaplastic thyroid cancer (ATC) under a
Special Protocol Assessment agreement with the U.S. Food and Drug Administration
(FDA). Phase II studies in platinum-resistant ovarian cancer and non-small cell
lung cancer are also ongoing. OXiGENE believes that ZYBRESTAT is poised to
become the first therapeutic product in a novel class of small-molecule drug
candidates called vascular disrupting agents (VDAs). Through interaction with
vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets
and collapses tumor vasculature, thereby depriving the tumor of oxygen and
causing death of tumor cells. In clinical studies in solid tumors, ZYBRESTAT
has demonstrated potent and selective activity against tumor vasculature, as
well as clinical activity against ATC, ovarian cancer, and various other solid
tumors. In clinical studies in patients with forms of macular degeneration,
intravenously-administered ZYBRESTAT has demonstrated clinical activity, and the
Company is working to develop a convenient and patient-friendly topical
formulation of ZYBRESTAT for ophthalmological indications.
-- more --
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases. The company's major focus is
developing VDAs that selectively disrupt abnormal blood vessels associated with
solid tumor progression and visual impairment. OXiGENE is dedicated to
leveraging its intellectual property and therapeutic development expertise to
bring life-extending and -enhancing medicines to patients.
Safe Harbor Statement
This news release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Any or all of the
forward-looking statements in this press release may turn out to be wrong.
Forward-looking statements can be affected by inaccurate assumptions OXiGENE
might make or by known or unknown risks and uncertainties, including, but not
limited to, enrollment rate for patients in the ZYBRESTAT pivotal trial for
anaplastic thyroid cancer, interim analysis of the same, timing of the IND
filing and Phase I trial initiation for topical ZYBRESTAT, timing of a Phase II
clinical trial of ZYBRESTAT and bevacizumab in NSCLC, timing or execution of a
strategic collaboration on any product or indication, and cash utilization rates
for 2008. Additional information concerning factors that could cause actual
results to materially differ from those in the forward-looking statements is
contained in OXiGENE's reports to the Securities and Exchange Commission,
including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE
undertakes no obligation to publicly update forward-looking statements, whether
because of new information, future events or otherwise. Please refer to our
Annual Report on Form 10-K for the fiscal year ended December 31, 2007.
# # #
OXiGENE Announces Clinical Trials Interim Data Update
| Source: Oxigene, Inc.